Stockscreener 앱 받기
2.67
8.10%
0.20
시간 외 거래:
2.68
0.01
+0.37%
Annovis Bio Inc 주식(ANVS)의 최신 뉴스
Annovis Bio partners with NeuroRPM for Parkinson’s trial monitoring - Investing.com
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial - markets.businessinsider.com
Neurorpm To Deploy Ai-Enabled Digital Biomarker Monitoring For Annovis Bio's Parkinson's Disease Clinical Trial - TradingView
Wearables track Parkinson's symptoms in Annovis drug study - Stock Titan
Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference - MSN
Shorts Report: Is Annovis Bio Inc stock forming a triangle pattern2026 Gainers & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Chart Watch: Should you avoid Annovis Bio Inc stock right now2026 Performance Recap & Low Risk High Win Rate Picks - baoquankhu1.vn
ANVS Technical Analysis & Stock Price Forecast - Intellectia AI
Annovis Bio Reports Promising Biomarker Results Showing Anti-Inflammatory, Neuroprotective Effects of Buntanetap in Alzheimer’s Patients - MSN
Phase 3 trial push deepens 2025 loss at Annovis Bio (NYSE: ANVS) - Stock Titan
Annovis Bio shares are trading higher. The company reported Q4 financial results.Annovis Bio (NYSE:ANVS) - Benzinga
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results - Bitget
Annovis Bio, Inc. Announces Business Updates and Financial Results for Fiscal Year 2025, Highlighting Pivotal Advances in Buntanetap Development for Neurodegenerative Diseases - Quiver Quantitative
Annovis Bio Q4 EPS $(0.39) Misses $(0.34) EstimateAnnovis Bio (NYSE:ANVS) - Benzinga
Annovis Bio (ANVS) Stock Analysis Report | Financials & Insights - Benzinga Japan
Annovis Bio to present buntanetap clinical data at AD/PD 2026 conference - MSN
Annovis Bio (NYSE: ANVS) outlines late-stage Alzheimer’s and Parkinson’s program - Stock Titan
Annovis Bio’s Buntanetap: Advancing Clinical Development for Alzheimer’s and Parkinson’s Disease with Novel Multi-Targeted Approach 33 - Minichart
Annovis Bio (NYSE:ANVS) Releases Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
Annovis Bio 10-K: Net loss $28.9M; Cash $19.5M, runway into Q3 2026 - TradingView
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MSN
Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Annovis Bio (ANVS) Short Interest & Short Float | Updated Mar 2026 $ANVS - MarketBeat
Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Friday - MarketBeat
ANVS|Annovis Bio Inc|Price:2.490|Chg%:-0.09 - TradingKey
Published on: 2026-03-11 14:44:25 - baoquankhu1.vn
Annovis Bio to Present Buntanetap Clinical Data at AD/PD 2026 Conference - MyChesCo
Support Test: Is Annovis Bio Inc. stock technically oversold2026 WrapUp & Technical Confirmation Trade Alerts - baoquankhu1.vn
Annovis Bio Secures NYSE Approval to Regain Compliance with Listing Standards - MSN
Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia - MSN
Momentum Shift: What makes Annovis Bio Inc stock attractive todayM&A Rumor & Fast Gain Stock Tips - baoquankhu1.vn
Annovis Bio Stock Price Drops 8.5%What's Next? - National Today
Annovis Bio (NYSE:ANVS) Stock Price Down 8.5%What's Next? - MarketBeat
Annovis CEO eyes spring breakthrough for Alzheimer’s drug - Longevity.Technology
Annovis Announces Two Presentations at the AD/PD 2026 International Conference - Bitget
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference - The Manila Times
AI Stocks: Will Annovis Bio Inc. benefit from rising consumer demandTrade Exit Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Annovis Bio Stock: Can Fresh Alzheimer’s Data Spark the Next Big Short Squeeze? - AD HOC NEWS
ANVS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Annovis nears FDA threshold for Alzheimer's drug as CEO eyes spring milestone - The Business Journals
Tech Rally: Whats the analyst consensus on Annovis Bio Inc2025 Buyback Activity & AI Powered Market Entry Ideas - baoquankhu1.vn
Annovis Bio (ANVS): Alzheimer’s Data, Cash Burn and Why Traders Are Split - AD HOC NEWS
Should you avoid Annovis Bio Inc. stock right nowEarnings Recap Summary & Weekly Setup with ROI Potential - mfd.ru
Trading Action: Will Annovis Bio Inc. benefit from seasonalityJuly 2025 Weekly Recap & Technical Pattern Based Signals - mfd.ru
Is Annovis Bio Inc. a defensive stockJuly 2025 Final Week & Safe Capital Growth Trade Ideas - mfd.ru
Aug Analyst Calls: Will Annovis Bio Inc benefit from seasonalityQuarterly Market Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Rate Hike: Can ADSE keep up with sector leadersJuly 2025 Setups & Verified Entry Point Detection - baoquankhu1.vn
Malvern-based Annovis continues phase 3 Alzheimer’s trial after safety review - MSN
Malvern-Based Annovis Continues Phase 3 Alzheimer’s Trial After Safety Review - MyChesCo
Will Annovis Bio Inc. stock rally after Fed decisionsJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - mfd.ru
Can Annovis Bio Inc. disrupt its industryJuly 2025 Institutional & Real-Time Volume Triggers - mfd.ru
ANVS Should I Buy - Intellectia AI
Annovis Bio Advances Alzheimer’s Phase 3 Trial After Safety Nod - The Globe and Mail
Guidance Update: Will Annovis Bio Inc. stock recover after earningsJuly 2025 Highlights & Low Risk Growth Stock Ideas - mfd.ru
Annovis Bio, Inc. Secures DSMB Approval for Phase 3 Trial - TradingView
Annovis Bio Receives Positive Safety Recommendation from DSMB for Buntanetap in Alzheimer's Phase 3 Trial - Quiver Quantitative
Annovis Bio, Inc. (ANVS) recently announced that its independent Data Safety Monitoring Board (DSMB) has officially approved the company to proceed with the pivotal Phase III clinical trial of Buntanetap for the treatment of Alzheimer's disease. - Bitget
1.20%
0.06%
자본화:
|
볼륨(24시간):